Dexcom, the Nasdaq-listed continuous glucose monitoring maker, opened its Athenry plant in Co Galway as its primary factory for Europe, the Middle East and Africa.
The €300 million facility is expected to create more than 1,000 jobs, The Irish Times reported.
Construction began nearly three years ago, and the site already counts 500 workers on its payroll. The plant is Dexcom’s first production base outside the United States and the Asia-Pacific region, and it arrives at a moment when the company’s growth is shifting weight toward international markets.
The numbers behind the move are straightforward. Dexcom reported $1.34 billion (€1.22 billion) in revenue for the third quarter of this year, an 11% increase year-over-year, according to the organisation. But the geographic split tells a different story: international revenue grew 5%, and Athenry is the answer management has built to serve that region.
“An important part of our growth comes from the EMEA region and that’s where this plant is built to serve,” said Jake Leach, Dexcom, in an interview with The Irish Times.

Dexcom Invests €300m in Athenry Plant to Double Workforce
- Dexcom has committed about €300 million to Athenry, its only EMEA production site, with headcount planned to double from 500 to more than 1,000.
- International revenue grew 5% in Q3 against 11% company-wide, and the plant is the capacity bet behind the push to serve that region.
- The west of Ireland medtech cluster — some 16,000 workers across Galway, Mayo and Roscommon, according to Dexcom — supplied the talent pool that made the location viable.
Why Dexcom Chose Athenry Over Anywhere Else
Leach, who has worked at Dexcom for more than two decades, framed the decision as a mix of logistics and labour. “I think there’s an awareness within the west of Ireland of medical technologies; there’s a skill set there that we were really looking for,” he told The Irish Times. He pointed to motorway access and public transit links as practical factors in the site selection.
The recruitment pitch mattered too. “Being able to recruit the talent we need for all different job categories: engineering, HR, IT, operations, technicians,” Leach listed as another draw. Hiring started well before the doors opened — engineering teams were brought on early and sent to Dexcom’s other plants, including San Diego, to train on the technology before production ramped up at home.
The strategy's calculations show… Sensors for glucose monitoring are high-volume products, and shipping them across oceans adds cost and complexity. Leach was blunt about the alternative: “The last thing we want to be doing is flying sensors all over the world. The idea is to put the plants close to where the people who are using the products are.”
A €300 Million Bet on Double-Digit Growth
Founded in 1999, Dexcom grew into a continuous glucose monitoring leader from its San Diego base.
The company says it has grown at a double-digit rate for many years, and Leach ties that directly to sensor volume: “We’ve been growing at a double-digit rate for many years and it really comes from more and more people using our technology to better manage their diabetes – with that, comes the need to produce more and more sensors.”
The facility’s role is to convert that demand into local supply. Before Athenry, every sensor sold in Europe, the Middle East and Africa came from US or Asia-Pacific lines. The new plant removes that dependency and shortens the supply chain for a region where Dexcom is now chasing market share.
| Metric | Figure | Context |
|---|---|---|
| Total investment | ~€300 million | Construction began nearly three years ago |
| Jobs expected | More than 1,000 | 500 already on site, per Leach |
| West of Ireland medtech employment | ~16,000 | Galway, Mayo and Roscommon, per Dexcom |
What the Local Cluster Gains
For Galway and the wider western region, the opening adds a global-name anchor to an existing cluster. Dexcom’s visibility in Ireland already runs deep through its sponsorship of Connacht Rugby’s home stadium in Galway city, and the company says its goal is “to be really be a member of the community.”
Leach’s stated ambition for the region is broad. “We’ve seen some really high-quality skill sets in the folks that we’ve hired and I’m really looking forward to seeing them grow,” he told The Irish Times.
The Wider Signal for Ireland’s Medtech Economy
The investment lands in a region that already functions as a medtech production hub for the State and the wider EU. That Dexcom chose to expand there — rather than concentrate capacity in the US or Asia-Pacific — is a vote for the cluster’s depth, and the company’s own words on talent make the reasoning explicit.
“We’re very focused on getting this technology to all the people that can benefit from it around the globe, not just the United States,” Leach said.
Dexcom was founded in 1999 and went public in 2005, trading on the Nasdaq under the ticker symbol DXCM. The company received its first FDA approval in 2006 and launched its first continuous glucose monitoring system that year. In 2020, Dexcom joined the Nasdaq-100 index, replacing American Airlines Group, and in October 2024, Time Magazine named its Stelo over-the-counter glucose monitor one of the year’s best inventions.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.